Prosecution Insights
Last updated: November 04, 2026
Application No. 18/688,453

HYDROCEPHALUS SHUNT

Final Rejection §102§103
Filed
Mar 01, 2024
Priority
Sep 03, 2021 — provisional 63/240,585 +1 more
Examiner
KIM, ERIN ASA
Art Unit
3781
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Cerulean Scientific Inc.
OA Round
2 (Final)
69%
Grant Probability
Favorable
3-4
OA Rounds
5m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 69% — above average
69%
Career Allowance Rate
70 granted / 101 resolved
-0.7% vs TC avg
Strong +34% interview lift
Without
With
+34.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
22 currently pending
Career history
125
Total Applications
across all art units

Statute-Specific Performance

§101
1.6%
-38.4% vs TC avg
§103
60.0%
+20.0% vs TC avg
§102
19.7%
-20.3% vs TC avg
§112
17.1%
-22.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 101 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Arguments Applicant’s arguments with respect to claim(s) 1-2, 32, and 36 have been considered but are moot because the new ground of rejection does not rely on any reference applied in the prior rejection of record for any teaching or matter specifically challenged in the argument. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1-2, 26-28, 32, and 36 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Koullick et al. (US 20040220510 A1). Regarding claim 1, Koullick discloses a ventricular catheter portion of a hydrocephalus shunt (10) comprising: a proximal end portion (B, annotated fig. 2) and a distal end portion (A, fig. 1 and annotated fig. 2, para. [0036]; note that the claim does not explicitly denote where each portion starts or ends); wherein the proximal end portion (B, annotated fig. 2) is comprised of tubing (11) terminating in a proximal tip (22, para. [0036, 0056], fig. 2), wherein the tubing comprises a first material which comprises a fluorinated material (agent 20 is positioned in or on the surface of the shunt 10, para. [0039]; the agent may be coated onto or impregnated into the material utilized to produce the shunt walls and may be fluoropolymers or polytetrafluoroethylenes, para. [0054]); wherein the distal end portion (A) is comprised of tubing (wall structure 26, para. [0056]) that is comprised of a second material selected from the group consisting of a non-fluorinated polymer, non-perfluorinated polymer, silicone elastomer (biocompatible elastomer material, such as silicone, para. [0006, 0056]), fluorosilicone elastomer, or perfluorosilicone elastomer; and wherein the tubing of the proximal end portion and the tubing of the distal end portion have a lumen (28) with an open end of the lumen distal to the proximal tip (annotated fig. 2). PNG media_image1.png 522 422 media_image1.png Greyscale Regarding claim 2, Koullick discloses the device of claim 1 and further discloses wherein the first material comprises one or more of: PFA, PTFE (para. [0054]), FEP, ePTFE, EFEP, ETFE, PVDF, VF2/HFP, VF2/tetrafluoro ethylene/HFP terpolymer, a fluoroelastomer, and/or a perfluoroelastomer. Regarding claim 26, Koullick discloses a method of making a ventricular catheter portion of a medical device according to claim 1, the method comprising preparing all or part of the proximal end portion or the distal end portion by one or more of: machining away excess material, drilling, laser cutting, laser drilling, extrusion, co-extrusion, injection molding, compression molding, melt spinning, electrospinning, dip coating (para. [0054]), blowing, foaming, over-molding, and chemical vapor deposition. Regarding claim 27, Koullick discloses the method of claim 26 and further discloses wherein the proximal portion and/or distal end portion comprise a fluoropolymer and/or perfluoropolymer present on at least a portion of their exterior surfaces (32, para. [0056]), wherein the fluoropolymer or perfluoropolymer containing exterior surface is formed by a method selected from the group consisting of: extrusion, co-extrusion, injection molding, compression molding, melt spinning, electrospinning, dip coating (para. [0054]), blowing, and/or foaming. Regarding claim 28, Koullick discloses a ventricular catheter portion of a hydrocephalus shunt (10) made by the method of claim 26 (para. [0005, 0056]). Regarding claim 32, Koullick discloses a hydrocephalus shunt (10) comprising a ventricular catheter portion (para. [0067]) of claim 1. Regarding claim 36, Koullick discloses a method of treatment comprising implanting the hydrocephalus shunt of claim 32 in an animal (para. [0005]). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 4, 8, 20-25, 29-30 is/are rejected under 35 U.S.C. 103 as being unpatentable over Koullick et al. (US 20040220510 A1) in view of Jones et al. (WO 2020077161 A1). Regarding claim 4, Koullick discloses the device of claim 1 but fails to disclose wherein the first material comprises ePTFE. Jones teaches a similar device in the same field of endeavor comprising ePTFE (para. [0030]). Koullick discloses PTFE, not ePTFE and it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have used ePTFE as shown in Jones with predictable results, namely, a flexible and porous material commonly used for medical implants. Regarding claim 8, Koullick discloses the device of claim 1 and further discloses wherein the distal end portion (A) comprises a tube comprised of a silicone elastomer (para. [0006, 0056]), fluorosilicone elastomer, and/or perfluorosilicone elastomer; and wherein the tubing of the distal end portion (A) is mechanically attached to the tubing (11) of the proximal end portion to create a ventricular catheter portion having a continuous lumen (28, fig. 1 and annotated fig. 2). However, Koullick fails to disclose the tubing of the proximal end portion is comprised of ePTFE. Jones teaches ePTFE (para. [0030]). Koullick discloses PTFE, not ePTFE and it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have used ePTFE as shown in Jones with predictable results, namely, a flexible and porous material commonly used for medical implants. Regarding claim 20, Koullick discloses the device of claim 1. However, Koullick fails to disclose wherein at least a portion of a surface of the proximal end portion, or a portion of a surface of both the proximal end portion and the distal end portion is coated with one or more fluorinated liquids, one or more perfluorinated liquids, or a combination of one or more fluorinated liquids and/or one or more perfluorinated liquids. Jones teaches wherein the medical device is coated with one or more fluorinated liquids, one or more perfluorinated liquids, or a combination of one or more fluorinated liquids and/or one or more perfluorinated liquids (para. [0027, 0040]). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to incorporate the liquid coating as shown in Jones to prevent thrombus formation, cell adhesion, and biofilm adhesion/growth (para. [0040]). Regarding claim 21, the combination of Koullick and Jones discloses the device of claim 20. However, Koullick fails to disclose wherein the fluorinated liquid, the perfluorinated liquid, or the combination of one or more fluorinated liquids and/or one or more perfluorinated liquids comprises a fluoroalkane or perfluoroalkane. Jones teaches wherein the fluorinated liquid, the perfluorinated liquid, or the combination of one or more fluorinated liquids and/or one or more perfluorinated liquids comprises a fluoroalkane or perfluoroalkane (para. [0027, 0033]). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to incorporate the liquid coating as shown in Jones to prevent thrombus formation, cell adhesion, and biofilm adhesion/growth (para. [0040]). Regarding claim 22, the combination of Koullick and Jones discloses the device of claim 20. However, Koullick fails to disclose wherein greater than 50%, 75%, 80%, or 90%, or 100%, of an exterior surface of the proximal end portion, the distal end portion, or both the proximal end portion and the distal end portion is comprised of a fluoropolymer and/or perfluorinated polymer and is coated with the fluorinated liquid, perfluorinated liquid, or a combination of one or more fluorinated liquids and/or perfluorinated liquids. Jones teaches wherein greater than 50%, 75%, 80%, or 90%, or 100%, of an exterior surface of the proximal end portion, the distal end portion, or both the proximal end portion and the distal end portion is comprised of a fluoropolymer and/or perfluorinated polymer and is coated with the fluorinated liquid, perfluorinated liquid, or a combination of one or more fluorinated liquids and/or perfluorinated liquids (para. [0027, 0045]). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to incorporate the liquid coating as shown in Jones to prevent thrombus formation, cell adhesion, and biofilm adhesion/growth (para. [0040]). Regarding claim 23, the combination of Koullick and Jones discloses the device of claim 20. However, Koullick fails to disclose wherein the one or more fluorinated liquids, the one or more perfluorinated liquids, or the combination of one or more fluorinated liquids and/or perfluorinated liquids comprises, consists essentially of, or consists of one or more perfluorinated liquids. Jones teaches wherein the one or more fluorinated liquids, the one or more perfluorinated liquids, or the combination of one or more fluorinated liquids and/or perfluorinated liquids comprises, consists essentially of, or consists of one or more perfluorinated liquids (para. [0027, 0030, 0033]). Regarding claim 24, the combination of Koullick and Jones discloses the device of claim 20. However, Koullick fails to disclose wherein the one or more fluorinated liquids, the one or more perfluorinated liquids, or the combination of one or more fluorinated liquids and/or one or more perfluorinated liquids comprises greater than: (i) 50%, 60%, 70%, 80%, 90%, 95%, or 98% of one or two fluorinated and/or perfluorinated compounds on a weight basis; (ii) 50%, 60%, 70%, 80%, 90%, 95%, or 98% of fluorinated compounds on a weight basis; (iii) 50%, 60%, 70%, 80%, 90%, 95%, or 98% of perfluorinated compounds on a weight basis; or (iv) 50%, 60%, 70%, 80%, 90%, 95%, or 98% of fluorinated and/or perfluorinated compounds on a weight basis. Jones teaches a variety of fluorinated and/or perfluorinated liquids, their potential compounds, and that a combination can be used (para. [0033]) but does not expressly disclose percentages by weight of the various compounds. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have modified the liquid of Jones to have a composition as any of the many options listed above as a matter of routine optimization since it has been held that “where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." MPEP 2144.05. Regarding claim 25, the combination of Koullick and Jones discloses the device of claim 20. However, Koullick fails to disclose wherein the one or more fluorinated liquids, the one or more perfluorinated liquids, or the combination of one or more fluorinated liquids and/or one or more perfluorinated liquids comprises: perfluoropropane, perfluorobutane, perfluoropentane, perfluorohexane, perfluorooctane, perfluorodecalin, perfluoroperhydrophenanthrene, perfluorooctylbromide, perfluoro tributyl amine, perfluorotripentyl amine, poly(hexa)fluoropropylene oxide, or combinations thereof. Jones teaches wherein the one or more fluorinated liquids, the one or more perfluorinated liquids, or the combination of one or more fluorinated liquids and/or one or more perfluorinated liquids comprises: perfluoropropane, perfluorobutane, perfluoropentane, perfluorohexane, perfluorooctane, perfluorodecalin, perfluoroperhydrophenanthrene, perfluorooctylbromide, perfluoro tributyl amine, perfluorotripentyl amine, poly(hexa)fluoropropylene oxide, or combinations thereof (para. [0033]). Regarding claim 29, Koullick discloses the device of claim 1. However, Koullick fails to disclose wherein the catheter is packaged in a sterile nonporous container coated with one or more fluorinated liquids, one or more perfluorinated liquids, or a combination of one or more fluorinated liquids and/or one or more perfluorinated liquids. Jones teaches a medical device packaged in a sterile nonporous (liquid tight seal cover, para. [0012]) container coated with one or more fluorinated liquids, one or more perfluorinated liquids, or a combination of one or more fluorinated liquids and/or one or more perfluorinated liquids (para. [0012, 0033]). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have incorporated the packaging of Jones for the device of Koullick to maintain sterility of the device and prevent thrombus formation, cell adhesion, and biofilm adhesion/growth (para. [0040]). Regarding claim 30, Koullick discloses the catheter of claim 1. However, Koullick fails to disclose wherein the catheter is packaged in a sterile nonporous container in the absence of one or more fluorinated liquids, one or more perfluorinated liquids, or a combination of one or more fluorinated liquids and/or one or more perfluorinated liquids; where the package either further comprises or is accompanied by a sterile aliquot of the one or more fluorinated liquids, one or more perfluorinated liquids, or the combination of one or more fluorinated liquids and/or one or more perfluorinated liquids. Jones teaches a medical device packaged in a sterile nonporous (liquid tight seal cover, para. [0012]) container in the absence of one or more fluorinated liquids, one or more perfluorinated liquids, or a combination of one or more fluorinated liquids and/or one or more perfluorinated liquids (para. [0007-0008, 0012]); where the package either further comprises or is accompanied by a sterile aliquot of the one or more fluorinated liquids, one or more perfluorinated liquids, or the combination of one or more fluorinated liquids and/or one or more perfluorinated liquids (para. [0036]). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have incorporated the packaging of Jones for the device of Koullick to maintain sterility of the device and prevent thrombus formation, cell adhesion, and biofilm adhesion/growth (para. [0040]). Claim(s) 3, 5, and 6 is/are rejected under 35 U.S.C. 103 as being unpatentable over Koullick et al. (US 20040220510 A1) in view of Forcucci et al. (US 20160022970 A1). Regarding claim 3, Koullick discloses the device of claim 1 and wherein the first material is a fluoropolymer. However, Hooven fails to disclose wherein the first material is a porous fluoropolymer, a porous perfluoropolymer, or a porous fluoropolymer-perfluoropolymer combination. Forcucci teaches a medical implant wherein the material is a porous fluoropolymer, a porous perfluoropolymer, or a porous fluoropolymer-perfluoropolymer combination (unexpanded PTFE, para. [0137]). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have modified the fluoropolymer of Koullick to be a flexible, biocompatible, non-absorbable material like porous PTFE (para. [0137]). Regarding claim 5, the combination of Koullick and Forcucci discloses the device of claim 3. Koullick further discloses wherein the second material of the catheter comprises an elastomer, silicone (para. [0006, 0056]), fluorosilicone, perfluorosilicone, or polyurethane. Regarding claim 6, the combination of Koullick and Forcucci discloses the device of claim 5. Koullick further discloses wherein the section where the tubing of the proximal end portion and the tubing of the distal end portion join or overlap extends from 0 to 1 cm (the overlap is 0 cm, see fig 1 and annotated fig. 2), from 1 cm to 2 cm, from 2 cm to 3 cm, from 3 cm to 4 cm, from 4 cm to 5 cm, from 5 cm to 6 cm, from 6 cm to 7 cm, from 7 cm to 8 cm, from 8 cm to 9 cm, from 9 cm to 10 cm, from 10 cm to 11 cm, from 11 cm to 12 cm, from 12 cm to 13 cm, or from 13 cm to 14 cm. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ERIN A KIM whose telephone number is (703)756-4738. The examiner can normally be reached Monday - Friday 8:00 am - 5:00 pm (EST). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Rebecca Eisenberg can be reached at (571) 270-5879. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ERIN A KIM/Examiner, Art Unit 3781 /SUSAN S SU/Primary Examiner, Art Unit 3781 22 October 2026
Read full office action

Prosecution Timeline

Mar 01, 2024
Application Filed
Mar 03, 2026
Non-Final Rejection mailed — §102, §103
Sep 03, 2026
Response Filed
Oct 26, 2026
Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778818
ABSORBENT ARTICLE FOR FLUID MANAGEMENT
3y 5m to grant Granted Nov 03, 2026
Patent 12778264
APPLICATOR
2y 9m to grant Granted Nov 03, 2026
Patent 12773487
SYSTEM AND METHOD FOR ELECTROCHEMICALLY FILTERING A BODILY FLUID IN THE TREATMENT OF ALZHEIMERS DISEASE AND OTHER DISEASES
2y 7m to grant Granted Oct 27, 2026
Patent 12751898
Needleless Vial Stopper
2y 7m to grant Granted Oct 06, 2026
Patent 12746144
URINE COLLECTION CONTAINER BAFFLE STRUCTURES, AND RELATED SYSTEMS AND METHODS
2y 11m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
69%
Grant Probability
99%
With Interview (+34.3%)
3y 1m (~5m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 101 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month